IL-1RA Compositions for Scarless Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current wound healing technologies face challenges in effectively treating chronic wounds and reducing scar formation, particularly due to prolonged inflammatory responses and dysregulation of fibro-proliferative processes, which often result in delayed healing or hypertrophic scarring, especially in diabetic patients.
Innovation Solution
The use of compositions comprising IL-1RA substitutes, such as anakinra, and human stem cells that express IL-1RA, including gingiva-derived mesenchymal stem cells, which can be administered to treat wounds and reduce scar formation by modulating inflammatory responses and promoting scarless healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional wound healing treatment is applied, then wound closure occurs through fibro-proliferative response, but scar formation increases due to prolonged inflammatory response
Solution Approach 1:
The patent converts the harmful prolonged inflammatory response into a beneficial outcome by using IL-1RA to modulate inflammation. Instead of suppressing inflammation completely, the invention uses the inflammatory response itself as a signaling mechanism while controlling its duration and intensity through IL-1RA treatment, thereby achieving wound closure with minimal scarring.
Solution Approach 2:
The patent changes the temporal and intensity parameters of the inflammatory response by administering IL-1RA. This modifies the inflammatory profile from prolonged and intense (causing scarring) to controlled and time-limited (promoting regeneration), thereby resolving the contradiction between effective healing and scar formation.
2Duration of action of moving object
If prolonged inflammatory response occurs, then wound healing process continues, but myofibroblasts and fibrocytes produce larger scar formation
Solution Approach 1:
The patent applies periodic action by using IL-1RA to create a controlled temporal pattern of inflammation. The treatment establishes a defined inflammatory phase that is activated when needed (at wound site) and terminated by IL-1RA action, preventing the prolonged continuous inflammation that leads to excessive scarring.
Solution Approach 2:
The patent implements feedback control where IL-1RA responds to the presence of inflammatory mediators at the wound site. The antagonist binds to IL-1 receptors and provides negative feedback that limits the duration and intensity of the inflammatory response, preventing scar formation while maintaining necessary healing functions.
3Productivity
If fibro-proliferative response is enhanced for wound closure, then healing speed increases, but scar formation increases
Solution Approach 1:
The patent applies local quality by creating different tissue outcomes in different regions. Through controlled IL-1RA treatment, the wound center achieves rapid closure while the surrounding tissue maintains a regenerative phenotype with minimal scarring. This spatial differentiation of healing quality resolves the contradiction between speed and scar formation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions improve wound healing by reducing inflammatory cell infiltration, enhancing collagen deposition, and minimizing scar formation, as demonstrated by accelerated wound closure and reduced scar area in both animal models and human treatments.
Implementation Method 1
compositions comprising an IL-1RA substitute and at least one human stem cell that expressed IL-1RA... to treat a wound and/or to reduce scar formation
Data Source
Figure 1
Figure 2A~2B
Figure 2C~2D
AI summary
This disclosure relates to a stem cell treatment. This disclosure also relates to an IL-1RA treatment. This disclosure also relates to a composition comprising stem cells and preparation of this composition. This disclosure also relates to a composition comprising IL-1RA, an IL-1RA substitute, or a combination thereof. This disclosure also relates to preparation of this composition. This disclosure further relates to a wound treatment using a composition comprising IL-1RA, an IL-1RA substitute, or a combination thereof. This disclosure also further relates to a treatment to reduce scar formation by using a composition comprising IL-1RA, an IL-1RA substitute, or a combination thereof.